We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Ogivri

News List

Mylan, Biocon Launch Trastuzumab Biosimilar, Ogivri in the U.S. americanpharmaceuticalreview
December 30, 2019
Mylan and Biocon announced the U.S. launch of Ogivri™ (trastuzumab-dkst), a biosimilar to Herceptin® (trastuzumab).
Biocon, Mylan launch Ogivri in Australia biospectrumasia
August 04, 2019
Ogivri is the first trastuzumab biosimilar approved and launched in Australia and available on the Pharmaceutical Benefits Scheme (PBS).
Biocon, Mylan launch first Trastuzumab Biosimilar Ogivri in Australia biospectrumasia
August 01, 2019
Ogivri is the first trastuzumab biosimilar approved and launched in Australia and available on the Pharmaceutical Benefits Scheme (PBS).
European Commission okays Mylan, Biocon’s biosimilar of cancer drug expressbpd
December 20, 2018
Ogivri is indicated for the treatment of patients with HER2 positive early breast cancer, metastatic breast cancer and metastatic gastric cancer
Ogivri approved as the first biosimilar against certain breast and stomach cancers europeanpharmaceuticalreview
December 05, 2017
The FDA has approved Ogivri as a biosimilar to Herceptin for the treatment of patients with breast or metastatic stomach cancer whose tumours overexpress the HER2 gene…